Kurizine-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor (CysLT1), mitigating bronchoconstriction, inflammation, and mucus production commonly seen in asthma and allergic rhinitis. The synergistic action of these agents offers comprehensive management of allergic respiratory disorders by targeting multiple inflammatory pathways. Kurizine-M is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic urticaria, and as an adjunctive therapy in asthma to improve symptom control and reduce exacerbations. It is generally well-tolerated, with a favorable safety profile; common adverse effects may include headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision, especially in pediatric and elderly populations. Kurizine-M Tablet provides a convenient once-daily dosing regimen, enhancing patient compliance in managing allergic conditions.

Dosage & How to Use